In recent years, Shanghai has accelerated the construction of a biomedical innovation source highland, a high-end manufacturing highland, a talent gathering highland, and a policy supporting highland, and the innovative drug industry has developed rapidly
.
According to the data, the scale of Shanghai's biomedical industry is expected to exceed 700 billion yuan in 2021, and the industrial scale has reached a new level
.
It is reported that the "14th Five-Year Plan" for the development of The Biomedical Industry in Shanghai clearly states that Shanghai will aim at the development direction of "high-end, intelligent and internationalization" of the biomedical industry, deeply implement the "Zhangjiang R&D + Made in Shanghai" action, and accelerate the creation of a biomedical industry innovation highland with global influence and a world biomedical industry cluster
.
Based on innovation, in recent years, Shanghai pharmaceutical companies have also continuously accelerated the pace of
innovative drugs "going to sea".
For example, Hehuang Pharmaceutical will submit an application for the listing of fruquintinib in the United States by the end of this year, and plans to submit a listing application to the European Union and Japan within next year to provide a Chinese solution
for the worldwide problem of colorectal cancer.
The industry said that fruquintinib is closer to "going to sea" and is expected to become the first original innovative drug
directly listed abroad in Zhangjiang and even Shanghai.
It is reported that on September 8, Hehuang Medicine released the international multicenter phase III clinical positive data
on the treatment of refractory metastatic colorectal cancer with fruquintinib.
FresCO-2 international multicenter clinical trials have shown that fruquintinib therapy achieved statistically and clinically significant prolongations
in both primary endpoint overall survival (OS) and critical secondary endpoint progression-free survival (PFS) compared with placebo.
In addition, the author has learned that Shanghai Jiyu Pharmaceutical, a subsidiary of Jimin Trust Group, has recently reached an exclusive licensing agreement with Roche and its Genentech, in which Shanghai Jiyu exclusively licenses the development and commercialization rights of the oral androgen receptor (AR) degrader JMKX002992 with independent intellectual property rights to Genentech
in the world.
According to the data, JMKX002992 is a new oral AR degrader independently developed by Shanghai Jiyu Small Molecule Innovation Research Institute, androgen receptor is recognized as the driver of prostate cancer disease, JMKX002992 has therapeutic potential
for prostate cancer patients who are resistant to existing therapies.
Under the agreement, Genentech will acquire the exclusive development and commercialization rights of JMKX002992 worldwide and bear all development and commercialization costs
.
In return, Genentech will make a down payment of $60 million to Shanghai Jiyu and pay the corresponding development and commercialization milestones of up to $
590 million when the agreed milestones are reached.
In addition, Shanghai Jiyu will also receive a gradient commission based on net sales for the cooperative products
.
It can be seen from the above cases that there are currently two main models for Shanghai pharmaceutical companies to "go to sea", namely, direct listing abroad and external licensing
.
The latter is also a more common pattern
.
The data shows that in the past year or so, Zhangjiang Innovative Drugs has "borrowed ships to go to sea" through external licensing, and its actions have been frequent
.
From 2021 to August 2022, Zhangjiang Biomedical has accumulated nearly 20 foreign licensed transactions, with a total transaction amount of more than US$
7 billion.
Among them, in terms of quantity, Fuhong Henlin has 4 items, followed by Jiyu Pharmaceutical has 3 items; Junshi Bio and Platinum Medicine have 2 items
each.
Reger med set a record for more than a year, granting Eli Lilly an intellectual property license in December 2021 for a total transaction value of more than $
1.
5 billion.
In recent years, Shanghai's pharmaceutical industry has been developing rapidly, by 2025, the development level of Shanghai's biomedical industry will be significantly improved, the leading role in the coordinated development of the biomedical industry in the Yangtze River Delta will be more prominent, the international influence of industrial technology innovation sources will continue to increase, and the initial construction will become the core bearing place of the world's biomedical industry cluster, and the scale of the city's biomedical industry will exceed 1,000 billion yuan
.
The industry said that it is foreseeable that more and more Innovative Pharmaceutical Companies in Shanghai will "sail out to sea" and compete with foreign pharmaceutical companies in a differentiated manner
.
